James D. Rizzo, MD

Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English

Education

MD - Doctor of Medicine

Biography

Dr. Rizzo is an attending physician in the MCW adult HCT unit, with clinical interests in hematologic malignancies and late effects of HCT. He completed a fellowship in hematology/oncology and a Robert Wood Johnson fellowship in epidemiology and cost-effectiveness research at Johns Hopkins University and holds an MS degree in epidemiology from MCW. He has taken a leadership role in several American Society of Hematology initiatives and participated in several committees. He is also an active member of the American Society for Blood and Marrow Transplant Quality Outcomes, Standardization of Outcomes, and Evidence Based Review Steering Committees.

Research Interests

Dr. J. Douglas Rizzo has ten years of experience with the Center for International Blood and Marrow Transplant Research (CIBMTR) at the Medical College of Wisconsin, an internationally recognized research organization. In his role as CIBMTR Senior Scientific Director and CIBMTR program leader for observational research, he has had primary responsibility for data operations and management staff oversight. He is responsible for implementation of the Stem Cell Therapeutics Outcomes Database at the CIBMTR, part of the national C.W. Bill Young Cell Transplantation Program. His research interests include late effects and quality of life after Hematopoietic Cell Transplantation (HCT), access to HCT across gender and ethnic/racial groups and other health policy issues.

Comparison of Vital Status, Cause of Death, and Follow-Up after Hematopoietic Cell Transplantation in Linked Center for International Blood and Marrow Transplant Research and California Cancer Registry Data, 1991 to 2018.

(Valcarcel B, Schonfeld SJ, Meyer CL, Brunson A, Cooley JJP, Abrahão R, Wun T, Auletta JJ, Gadalla SM, Engels E, Albert PS, Spellman SR, Rizzo JD, Shaw BE, Muffly L, Keegan THM, Morton LM.) Transplant Cell Ther. 2024 Feb;30(2):239.e1-239.e11 PMID: 37981238 PMCID: PMC10872486 SCOPUS ID: 2-s2.0-85180597524 11/20/2023
Application of the CIBMTR One Year Survival Outcomes Calculator as a tool for retrospective analysis.

(Cho C, Devlin S, Maloy M, Horowitz MM, Logan B, Rizzo JD, Giralt SA, Perales MA.) Bone Marrow Transplant. 2023 Oct;58(10):1089-1095 PMID: 37422574 PMCID: PMC10592419 SCOPUS ID: 2-s2.0-85164194423 07/09/2023
Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research.

(Auletta JJ, Kou J, Chen M, Bolon YT, Broglie L, Bupp C, Christianson D, Cusatis RN, Devine SM, Eapen M, Hamadani M, Hengen M, Lee SJ, Moskop A, Page KM, Pasquini MC, Perez WS, Phelan R, Riches ML, Rizzo JD, Saber W, Spellman SR, Stefanski HE, Steinert P, Tuschl E, Yusuf R, Zhang MJ, Shaw BE.) Transplant Cell Ther. 2023 Jun;29(6):346.e1-346.e10 PMID: 36924931 PMCID: PMC10239334 SCOPUS ID: 2-s2.0-85153327578 03/17/2023
Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE).

(Saccardi R, Putter H, Eikema DJ, Busto MP, McGrath E, Middelkoop B, Adams G, Atlija M, Ayuk FA, Baldomero H, Beguin Y, de la Cámara R, Cedillo Á, Balari AMS, Chabannon C, Corbacioglu S, Dolstra H, Duarte RF, Dulery R, Greco R, Gusi A, Hamad N, Kenyon M, Kröger N, Labopin M, Lee J, Ljungman P, Manson L, Mensil F, Milpied N, Mohty M, Oldani E, Orchard K, Passweg J, Pearce R, de Latour RP, Poirel HA, Rintala T, Rizzo JD, Ruggeri A, Sanchez-Martinez C, Sanchez-Guijo F, Sánchez-Ortega I, Trnková M, Ferreiras DV, Wilcox L, de Wreede LC, Snowden JA.) Bone Marrow Transplant. 2023 Jun;58(6):659-666 PMID: 36894635 PMCID: PMC9995719 SCOPUS ID: 2-s2.0-85149466633 03/10/2023
Corrigendum to 'Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation' [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885].

(Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M.) Transplant Cell Ther. 2022 Oct;28(10):717 PMID: 36202527 SCOPUS ID: 2-s2.0-85101258094 10/07/2022
Corrigendum to 'Current Use and Trends in Hematopoietic Cell Transplantation in the United States' [Transplantation and Cellular Therapy 26/8 (2020) e177-e182].

(D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM.) Transplant Cell Ther. 2022 Oct;28(10):715-716 PMID: 36202526 SCOPUS ID: 2-s2.0-85108559179 10/07/2022
Adding Centralized Electronic Patient-Reported Outcome Data Collection to an Established International Clinical Outcomes Registry.

(Cusatis R, Flynn KE, Vasu S, Pidala J, Muffly L, Uberti J, Tamari R, Mattila D, Mussetter A, Bruzauskas R, Chen M, Leckrone E, Myers J, Mau LW, Rizzo JD, Saber W, Horowitz M, Lee SJ, Burns LJ, Shaw B.) Transplant Cell Ther. 2022 Feb;28(2):112.e1-112.e9 PMID: 34757219 PMCID: PMC8915447 SCOPUS ID: 2-s2.0-85121127060 11/11/2021
Corrigendum to ‘Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation’ [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885, (S1083879120304146), (10.1016/j.bbmt.2020.07.005)]

(Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M.) Transplantation and Cellular Therapy. October 2022;28(10):717 SCOPUS ID: 2-s2.0-85101258094 10/01/2022
Corrigendum to ‘Current Use and Trends in Hematopoietic Cell Transplantation in the United States’ [Transplantation and Cellular Therapy 26/8 (2020) e177-e182, (S1083879120302251), (10.1016/j.bbmt.2020.04.013)]

(D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM.) Transplantation and Cellular Therapy. October 2022;28(10):715-716 SCOPUS ID: 2-s2.0-85108559179 10/01/2022
COVID-19 and Hematopoietic Cell Transplantation Center-Specific Survival Analysis: Can We Adjust for the Impact of the Pandemic? Recommendations of the COVID-19 Task Force of the 2020 Center for International Blood and Marrow Transplantation Research Center Outcomes Forum.

(Wingard JR, Ahn KW, Dandoy C, Perales MA, Wood WA, Logan B, Riches M, Rizzo JD.) Transplant Cell Ther. 2021 Jul;27(7):533-539 PMID: 33895401 PMCID: PMC8061634 SCOPUS ID: 2-s2.0-85107113196 04/26/2021
The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill.

(Knight JM, Costanzo ES, Singh S, Yin Z, Szabo A, Pawar DS, Hillard CJ, Rizzo JD, D'Souza A, Pasquini M, Coe CL, Irwin MR, Raison CL, Drobyski WR.) Transl Psychiatry. 2021 Jan 18;11(1):58 PMID: 33462203 PMCID: PMC7812704 SCOPUS ID: 2-s2.0-85100097244 01/20/2021
Screening and prevention guidelines for hematopoietic cell transplant survivors

(Bhatt NS, Rizzo JD, Majhail NS.) Blood and Marrow Transplantation Long Term Management: Survivorship after Transplant: Second Edition. 1 January 2021:80-91 SCOPUS ID: 2-s2.0-85111047222 01/01/2021